Calendario›SNY›Dupilumab SAR231893 · REVEAL

Dupilumab SAR231893 · REVEAL

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

Ensayo de Sanofi en Asma.

Más ensayos de: Asma.

Fase

no aplica

Estado

Completado

Participantes

376

previstos

Centros

41

Fin del objetivo primario

jun 2026

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en nov 2020.

Qué mide

Baseline Characteristics: Socio-demographics (del registro, en inglés) (en el inicio)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPrimary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric oxide \[FeNO\]), and concomitant treatments for asthma. Secondary Objectives: The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT for asthma (eg, most commonly used regimens, reason for initiation of new asthma treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching) * To assess the effectiveness of DUPIXENT in asthma patients in a real world setting (lung function improvement, exacerbation rate, asthma control) * To assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects of treatment in comorbid conditions in asthma patients treated with Dupixent * To collect data on HealthCare Resource Utilization (HCRU) * To collect safety data on study participants in the real-world setting.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04550962), actualizada en jul 2026.